




The relative strengths and weaknesses of Elicio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Elicio Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Elicio Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 75% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	16,348
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,766
Liabilities, Non-Current	6,007
Other Assets	10,081
Other Compr. Net Income	-197
Other Expenses	0
Other Liabilities	0
Other Net Income	550
Other Revenues	0
Property and Equipment	717
Research and Development	23,849
Selling, General and Administrative Expense	11,896

Output Variable	Value in 1000 USD
Assets	27,146
Liabilities	15,773
Expenses	35,745
Revenues	0
Stockholders Equity	11,373
Net Income	-35,195
Comprehensive Net Income	-35,294
BaseVar	39,706
ECR before LimitedLiability	-49%
Economic Capital Ratio	138%